

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13G/A

REGENERON PHARMACEUTICALS INC  
Form SC 13G/A  
February 16, 2016

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO  
FILED PURSUANT TO Section 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. 1)

REGENERON PHARMACEUTICALS

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

75886F107

(CUSIP Number)

DECEMBER 31, 2015

(Date of Event which Requires Filing of Statement)

Check the appropriate box to designate the Rule pursuant to which this Schedule  
is filed:

Rule 13d - 1(b)

Rule 13d - 1(c)

Rule 13d - 1(d)

1 Name of Reporting Person

Sands Capital Management, LLC

2 Check the Appropriate Box if a Member of a Group

NOT APPLICABLE

3 SEC Use Only

---

4 Citizenship or Place of Organization

Delaware, United States

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13G/A

Number of Shares Beneficially Owned by Each Reporting Person With

5 Sole Voting Power: 2,753,356

6 Shared Voting Power: -0-

7 Sole Dispositive Power: 3,698,553

8 Shared Dispositive Power: -0-

9 Aggregate Amount Beneficially Owned by Each Reporting Person

3,698,553

10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

NOT APPLICABLE

11 Percent of Class Represented by Amount in Row 9

3.6% (1)

12 Type of Reporting Person

IA

---

(1) Based on 102,151,256 shares outstanding as reported in the Issuer's Form 10-Q as of October 16, 2015.

Item 1(a) Name of Issuer:

REGENERON PHARMACEUTICALS

Item 1(b) Address of Issuer's Principal Executive Offices:

777 Old Saw Mill River Road, Tarrytown, NY 10591

Item 2(a) Name of Person(s) Filing:

SANDS CAPITAL MANAGEMENT, LLC

Item 2(b) Address of Principal Business Office:

1101 WILSON BLVD., SUITE 2300, ARLINGTON, VA 22209

Item 2(c) Citizenship or Place of Organization:

# Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13G/A

DELAWARE, UNITED STATES

Item 2(d) Title of Class of Securities:

COMMON STOCK

Item 2(e) CUSIP Number: 75886F107

Item 3 If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
- (e)  An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
- (k)  Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 3,698,553

(b) Percent of class: 3.6%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 2,753,356

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13G/A

(ii) Shared power to vote or to direct the vote: None

(iii) Sole power to dispose or to direct the disposition of: 3,698,553

(iv) Shared power to dispose or to direct the disposition of: None

Item 5 Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ].

Item 6 Ownership of More than Five Percent on Behalf of Another Person

Not Applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not Applicable.

Item 8 Identification and Classification of Members of the Group.

Not Applicable.

Item 9 Notice of Dissolution of Group.

Not Applicable.

Item 10 Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sands Capital Management, LLC

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form SC 13G/A

Date: February 12, 2016

Signature: /s/ Lisa M. Grozio

Name & Title: Lisa M. Grozio, Chief Compliance Officer